Որոնման արդյունքները - Ramchandren, Radhakrishnan
- Ցուցադրվում են 1 - 20 արդյունքները 29
- Գնացեք Հաջորդ էջ
-
1
-
2
-
3
-
4
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study Goy, Andre, Sinha, Rajni, Williams, Michael E., Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas E.
Հրապարակվել է 2013Տեքստ -
5
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution SUKARI, AMMAR, NAGASAKA, MISAKO, ALHASAN, ROBA, PATEL, DHAVAL, WOZNIAK, ANTOINETTE, RAMCHANDREN, RADHAKRISHNAN, VAISHAMPAYAN, ULKA, WEISE, AMY, FLAHERTY, LAWRENCE, JANG, HYEJEONG, KIM, SEONGHO, GADGEEL, SHIRISH
Հրապարակվել է 2019Տեքստ -
6
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma Herrera, Alex F., Goy, Andre, Mehta, Amitkumar, Ramchandren, Radhakrishnan, Pagel, John M., Svoboda, Jakub, Guan, Shanhong, Hill, John S., Kwei, Kevin, Liu, Emily A., Phillips, Tycel
Հրապարակվել է 2019Տեքստ -
7
Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.
Հրապարակվել է 2016Տեքստ -
8
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia
Հրապարակվել է 2019Տեքստ -
9
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies Han, Tae H., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Chen, Robert, Matous, Jeffrey V., Cooper, Maureen, Grove, Laurie E., Alley, Stephen C., Lynch, Carmel M., O’Connor, Owen A.
Հրապարակվել է 2013Տեքստ -
10
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) p... Goy, Andre, Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas
Հրապարակվել է 2015Տեքստ -
11
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma Witzig, Thomas E., Zinzani, Pier Luigi, Habermann, Thomas M., Tuscano, Joseph M., Drach, Johannes, Ramchandren, Radhakrishnan, Besisik, Sevgi Kalayoglu, Takeshita, Kenichi, Bravo, Marie-Laure Casadebaig, Zhang, Lei, Fu, Tommy, Goy, Andre
Հրապարակվել է 2017Տեքստ -
12
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Gopal, Ajay K., Ramchandren, Radhakrishnan, O'Connor, Owen A., Berryman, Robert B., Advani, Ranjana H., Chen, Robert, Smith, Scott E., Cooper, Maureen, Rothe, Achim, Matous, Jeffrey V., Grove, Laurie E., Zain, Jasmine
Հրապարակվել է 2012Տեքստ -
13
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.
Հրապարակվել է 2021Տեքստ -
14
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres
Հրապարակվել է 2014Տեքստ -
15
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L., Rosenblatt, Joseph D., Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M., Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M., Kennedy, Dana A., Shustov, Andrei
Հրապարակվել է 2017Տեքստ -
16
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi
Հրապարակվել է 2017Տեքստ -
17
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.
Հրապարակվել է 2019Տեքստ -
18
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald
Հրապարակվել է 2020Տեքստ -
19
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.
Հրապարակվել է 2018Տեքստ -
20
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John
Հրապարակվել է 2022Տեքստ